Family planning considerations in people with multiple sclerosis.

Multiple sclerosis is often diagnosed in patients who are planning on having children. Although multiple sclerosis does not negatively influence most pregnancy outcomes, less is known regarding the effects of fetal exposure to novel disease-modifying therapies (DMTs). The withdrawal of some DMTs during pregnancy can modify the natural history of multiple sclerosis, resulting in a substantial risk of pregnancy-related relapse and disability. Drug labels are typically restrictive and favour fetal safety over maternal safety. Emerging data reporting outcomes in neonates exposed to DMTs in utero and through breastfeeding will allow for more careful and individualised treatment decisions. This emerging research is particularly important to guide decision making in women with high disease activity or who are treated with DMTs associated with risk of discontinuation rebound. As increasing data are generated in this field, periodic updates will be required to provide the most up to date guidance on how best to achieve multiple sclerosis stability during pregnancy and post partum, balanced with fetal and newborn safety.

• Publication year

  2023

• Venue

  Lancet Neurology

• Publication date

  2023-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/s1474-4422(22)00426-4PMID 36931808
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants.

  2022cited by this paper
• Peripartum disease activity in moderately and severely disabled women with multiple sclerosis

  2022cited by this paper
• Pregnancy Outcomes in Patients with Multiple Sclerosis Following Exposure to Ofatumumab

  2022cited by this paper
• Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis – COBRA study

  2022cited by this paper
• Pregnancy, Fetal, and Infant Outcomes Following Maternal Exposure to Glatiramer Acetate During Pregnancy and Breastfeeding

  2022cited by this paper
• Women with female infertility seeking medically assisted reproduction are not at increased risk of developing multiple sclerosis.

  2022cited by this paper
• Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis

  2022cited by this paper
• OUP accepted manuscript

  2022cited by this paper
• Peginterferon beta-1a concentrations in breast milk of lactating multiple sclerosis patients.

  2022cited by this paper
• Neonatal baclofen withdrawal following intrauterine exposure

  2022cited by this paper
• Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy

  2022cited by this paper
• Pregnancy outcomes following maternal or paternal exposure to teriflunomide in the Danish MS population.

  2022cited by this paper
• Pregnancy‐induced brain magnetic resonance imaging changes in women with multiple sclerosis

  2022cited by this paper
• Cladribine and pregnancy in women with multiple sclerosis: The first cohort study

  2022cited by this paper
• Assessing the Risk of Relapse Requiring Corticosteroids After In Vitro Fertilization in Women With Multiple Sclerosis

  2022cited by this paper
• Safety of breast feeding during rituximab treatment in multiple sclerosis

  2022cited by this paper
• Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis

  2021cited by this paper
• Brain MRI activity during the year before pregnancy can predict post-partum clinical relapses

  2021cited by this paper
• Treatment of Women with Multiple Sclerosis Planning Pregnancy

  2021cited by this paper
• Clinical and Radiologic Disease Activity in Pregnancy and Postpartum in MS

  2021cited by this paper
• Therapeutic plasma exchange in pregnancy: A literature review.

  2021cited by this paper
• Is pregnancy in MS patients safe and what is its impact on MS course? Real World evidence of 1533 pregnancies in Czech Republic.

  2021cited by this paper
• Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis

  2021cited by this paper
• Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry

  2021cited by this paper
• Pregnancy in women with MS: Impact on long-term disability accrual in a nationwide Danish Cohort

  2021cited by this paper
• Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists.

  2021cited by this paper
• Effects of Pregnancy and Breastfeeding on Clinical Outcomes and MRI Measurements of Women with Multiple Sclerosis: An Exploratory Real-World Cohort Study

  2021cited by this paper
• Apparent changes in the epidemiology and severity of multiple sclerosis

  2021cited by this paper
• Risk factors for peripartum depression in women with multiple sclerosis

  2021cited by this paper
• Fatigue as the limiting factor for vaginal birth in patients with multiple sclerosis.

  2021cited by this paper
• Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation

  2021cited by this paper
• Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening

  2021cited by this paper
• Rituximab and Canakinumab Use During Lactation: No Detectable Serum Levels in Breastfed Infants

  2021cited by this paper
• Pregnancy-Related and Perinatal Outcomes in Women With Multiple Sclerosis

  2021cited by this paper
• Perinatal Depression and Anxiety in Women With Multiple Sclerosis

  2021cited by this paper
• Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis

  2021cited by this paper
• Pregnancy and Fetal Outcomes Following Exposure to Modafinil and Armodafinil During Pregnancy.

  2020cited by this paper
• Reproductive history of the Danish multiple sclerosis population: A register-based study

  2020cited by this paper
• Effect of assisted reproductive technology on multiple sclerosis relapses: Case series and meta-analysis

  2020cited by this paper
• Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry

  2020cited by this paper
• Rebound after discontinuation of teriflunomide in patients with multiple sclerosis: 2 case reports.

  2020cited by this paper
• Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure

  2020cited by this paper
• Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort

  2020cited by this paper
• Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder

  2020cited by this paper
• Rituximab, MS, and pregnancy

  2020cited by this paper
• Associations Between Maternal Antenatal Corticosteroid Treatment and Mental and Behavioral Disorders in Children.

  2020cited by this paper
• Safety of potential breast milk exposure to IFN-β or glatiramer acetate

  2020cited by this paper
• A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project

  2020cited by this paper
• Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety

  2020cited by this paper
• Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.

  2020cited by this paper
• Transfer of monoclonal antibodies into breastmilk in neurologic and non-neurologic diseases

  2020cited by this paper
• Cladribine transfer into human milk: A case report

  2020cited by this paper
• Change in pregnancy-associated multiple sclerosis relapse rates over time: a meta-analysis.

  2020cited by this paper
• Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study

  2020cited by this paper
• Methylprednisolone Concentrations in Breast Milk and Serum of Patients with Multiple Sclerosis Treated with IV Pulse Methylprednisolone.

  2020cited by this paper
• MRI activity in MS and completed pregnancy

  2020cited by this paper
• Association of Pregnancy With the Onset of Clinically Isolated Syndrome.

  2020cited by this paper
• Delay from treatment start to full effect of immunotherapies for multiple sclerosis.

  2020cited by this paper
• Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab

  2020cited by this paper
• Live birth rates, infertility diagnosis, and infertility treatment in women with and without multiple sclerosis: Data from an administrative claims database.

  2020cited by this paper
• Ocrelizumab exposure in the second trimester of pregnancy without neonatal B-cell depletion.

  2020cited by this paper
• Dimethyl fumarate transfer into human milk

  2020cited by this paper
• Anti-CD20 therapies and pregnancy in neuroimmunologic disorders

  2020cited by this paper
• Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS: Stratification by maternal and newborn characteristics in a register-based cohort study in Finland and Sweden.

  2020cited by this paper
• Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis

  2019cited by this paper
• Pregnancy Outcomes in Patients Treated with Ocrelizumab

  2019cited by this paper
• Association Between Breastfeeding and Postpartum Multiple Sclerosis Relapses: A Systematic Review and Meta-analysis.

  2019cited by this paper
• Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis

  2019cited by this paper
• ACOG Committee Opinion No. 776: Immune Modulating Therapies in Pregnancy and Lactation.

  2019cited by this paper
• Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience

  2019cited by this paper
• Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions

  2019cited by this paper
• Multiple sclerosis in resource-limited settings

  2019cited by this paper
• Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence – an update

  2019cited by this paper
• Rituximab before and during pregnancy

  2018cited by this paper
• Five years before multiple sclerosis onset: Phenotyping the prodrome

  2018cited by this paper
• Natalizumab during pregnancy and lactation

  2018cited by this paper
• Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria

  2018cited by this paper
• Obstetric anesthesia/analgesia does not affect disease course in multiple sclerosis: 10‐year retrospective cohort study

  2018cited by this paper
• There is no benefit in the use of postnatal intravenous immunoglobulin for the prevention of relapses of multiple sclerosis: findings from a systematic review and meta-analysis

  2018cited by this paper
• Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis

  2018cited by this paper
• A global view of severe maternal morbidity: moving beyond maternal mortality

  2018cited by this paper
• Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica

  2018cited by this paper
• Male factor infertility and risk of multiple sclerosis: A register-based cohort study

  2018cited by this paper
• Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era

  2018cited by this paper
• Pregnancy decision-making in women with multiple sclerosis treated with natalizumab

  2018cited by this paper
• Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database.

  2017cited by this paper
• Evaluation of Potential Drug–Drug Interaction Between Delayed‐Release Dimethyl Fumarate and a Commonly Used Oral Contraceptive (Norgestimate/Ethinyl Estradiol) in Healthy Women

  2017cited by this paper
• Definitive childlessness in women with multiple sclerosis: a multicenter study

  2017cited by this paper
• Dramatic rebounds of MS during pregnancy following fingolimod withdrawal

  2017cited by this paper
• Peripartum depression in parents with multiple sclerosis and psychiatric disorders in children

  2016cited by this paper
• Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study

  2016cited by this paper
• Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect.

  2016cited by this paper
• Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes.

  2016cited by this paper
• Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility

  2016cited by this paper
• Transfer of Natalizumab into Breast Milk in a Mother with Multiple Sclerosis

  2015cited by this paper
• Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience

  2015cited by this paper
• Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study

  2015cited by this paper
• Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden

  2014cited by this paper
• Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs

  2014cited by this paper
• Natalizumab use during the third trimester of pregnancy.

  2014cited by this paper

• C5aR inhibitors: New dawn and challenges from pathophysiological mechanisms to clinical treatment

  2026cites this paper
• Unexpected pregnancy in a patient with AQP4-IgG + NMOSD after treatment with inebilizumab: a case report

  2026cites this paper
• Multiple Sclerosis in Women: Impact of Different Life Stages on Treatment Decisions

  2026influential citation
• Optimizing kiwifruit cultivar selection through integrated quality evaluation: An entropy weighted-analytic hierarchy process approach for balancing biochemical and sensory attributes

  2026cites this paper
• Genetic testing in multiple sclerosis: Parental attitudes in a Turkish sample

  2026cites this paper
• Disease-Modifying Therapy and Breastfeeding

  2026cites this paper
• A real-world study on persistence with ofatumumab in Canadian patients with multiple sclerosis.

  2026cites this paper
• Integrating Reproductive and Clinical Variables to Predict Postpartum Disability Outcomes in Multiple Sclerosis Using Machine Learning

  2026cites this paper
• Safety of breastfeeding under monoclonal antibodies in the offspring of mothers with multiple sclerosis or neuromyelitis optica spectrum disorder

  2026cites this paper
• Risk of postpartum disease activity with subcutaneous versus intravenous Natalizumab in pregnant women with multiple sclerosis.

  2026cites this paper
• Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGAD.

  2026cites this paper
• Association of Neurodevelopmental Disorders and Congenital Anomalies With Prenatal Multiple Sclerosis Treatment-Real-World Historical Cohort Study.

  2026cites this paper
• Persistent parvovirus B19 DNAemia in B-cell depletion: Implications for family planning in multiple sclerosis and related disorders.

  2026cites this paper
• Updates on the Acute and Maintenance Management of Optic Neuritis including multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody disease

  2026cites this paper
• Family planning in neuromyelitis optica spectrum disorder.

  2025cites this paper
• Impact of sex on multiple sclerosis therapy

  2025cites this paper
• Treatment Strategies and Disease Activity During Pregnancy and Postpartum: Real-World Data From the Swiss Multiple Sclerosis Cohort.

  2025cites this paper
• Disease-modifying therapy during pregnancy and postpartum relapse activity in women with multiple sclerosis undergoing assisted reproductive technology treatment: a nationwide cohort study

  2025cites this paper
• Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

  2025cites this paper
• A drug evaluation narrative review of cladribine as a treatment for multiple sclerosis.

  2025cites this paper
• Mental health outcomes in pregnant women with relapsing-remitting multiple sclerosis: a longitudinal cohort study

  2025cites this paper
• Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.

  2025cites this paper
• Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis.

  2025cites this paper
• Emergence of Anti-CD20 Therapies for Individuals With Multiple Sclerosis Planning Pregnancy.

  2025cites this paper
• Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability

  2025cites this paper
• Maternal and neonatal outcomes associated with natalizumab exposure during pregnancy in Iranian patients with multiple sclerosis.

  2025cites this paper
• Relapse activity after assisted reproductive technology treatments in women with multiple sclerosis: a nationwide cohort study in Denmark

  2025cites this paper
• Maternité et sclérose en plaques. Évolution des concepts et des prises en charge

  2025cites this paper
• Multiple sclerosis, fertility, pregnancy, and assisted reproductive technology: Current knowledge.

  2025cites this paper
• Multiple Sclerosis – Management and Disease Modulation in Pregnancy

  2025cites this paper
• Recommendations for the use of off-label rituximab for the treatment of multiple sclerosis in low-resource settings.

  2025cites this paper
• Relapse activity during pregnancy and the postpartum year is associated with accelerated disability progression in multiple sclerosis.

  2025cites this paper
• Transfer of interferon beta in term placentae.

  2025cites this paper
• A narrative review on the safety of glatiramer acetate in multiple sclerosis: focus on Europe

  2025cites this paper
• Cost effectiveness of different treatment strategies with natalizumab for pregnant women with multiple sclerosis

  2025cites this paper
• Ofatumumab-exposed breastfeeding in multiple sclerosis patients

  2025cites this paper
• Update in multiple sclerosis

  2025cites this paper
• A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status update

  2025cites this paper
• Study of the Association Between Menarche and Disease Course in Pediatric Multiple Sclerosis

  2025cites this paper
• Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2

  2025influential citation
• Central American and Caribbean consensus for the treatment of MS, NMOSD, and MOGAD.

  2025cites this paper
• Reduced childbirth rates in multiple sclerosis from the prodromal phase: Evidence from a population-based cohort study

  2025cites this paper
• Pregnancy and birth outcomes in women with multiple sclerosis: Comparison of the RESPONSE study to the general French population

  2025cites this paper
• The role of pregnancy in relapsing-remitting MS prognosis: A five-year study.

  2025cites this paper
• Long-Term Management and Therapeutic Sequencing for Patients with Relapsing Multiple Sclerosis in France: A Vignette Study

  2025cites this paper
• Impact of pregnancy on the maternal brain in health and multiple sclerosis

  2025cites this paper
• Multiple Sclerosis Disease-Modifying Treatment Algorithms: 2025 Positioning of the Portuguese Multiple Sclerosis Study Group.

  2025cites this paper
• De-escalating and discontinuing disease-modifying therapies in multiple sclerosis

  2024cites this paper
• Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines.

  2024cites this paper
• The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years—Protocol, recruitment status, and baseline characteristics

  2024cites this paper
• Safety of dermatologic medications in pregnancy and lactation: An Update - Part II: Lactation.

  2024cites this paper
• Eomesodermin-expressing CD4+ Th cells and association with pregnancy in multiple sclerosis

  2024cites this paper
• Schwangerschaft und Stillzeit bei Frauen mit Multipler Sklerose

  2024influential citation
• Male sexual and reproductive health in multiple sclerosis: a scoping review

  2024cites this paper
• Sex impacts treatment decisions in multiple sclerosis

  2024cites this paper
• Neonatal outcomes in women with Multiple Sclerosis - Influence of disease activity: A Danish nationwide cohort study.

  2024cites this paper
• Real‐world persistence of multiple sclerosis disease‐modifying therapies

  2024cites this paper
• Pregnancy and reproductive health in women with multiple sclerosis: an update

  2024cites this paper
• Immunosuppressants and Breastfeeding

  2024cites this paper
• Multiple sclerosis treatment review for primary care providers

  2024cites this paper
• Tildrakizumab in Psoriasis and Beyond

  2024cites this paper
• Clinical Experience with Dimethyl Fumarate and Natalizumab in Pregnant Women with Multiple Sclerosis: A Four-Patient Case Series

  2024cites this paper
• Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy

  2024cites this paper
• Guselkumab - In Psoriasis and Beyond

  2024cites this paper
• Study of the impact of multiple sclerosis on the reproductive life of Spanish women: An online survey.

  2024cites this paper
• Recommendations for the Treatment of Multiple Sclerosis in Family Planning, Pregnancy and Lactation in Switzerland: Immunotherapy

  2024cites this paper
• [The effect of pregnancy on multiple sclerosis].

  2024cites this paper
• B-cell Depletion Therapy in Pediatric Neuroinflammatory Disease

  2024influential citation
• Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy

  2024cites this paper
• Patient-centered pregnancy planning in multiple sclerosis: evidence for a new era

  2024influential citation
• Case report: Rapid symptom relief in autoimmune encephalitis with efgartigimod: a three-patient case series

  2024cites this paper
• Cesarian sections in women with multiple sclerosis: A Canadian prospective pregnancy study

  2024cites this paper
• Sex differences in use of potentially teratogenic disease modifying treatments for multiple sclerosis and degree of hormonal contraception overlap in women between 2007-2021: An Australian population-based study.

  2024cites this paper
• Revisiting risankizumab: a newer biologic drug in dermatology.

  2024cites this paper
• Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies

  2024cites this paper
• Impact of Continuous Ofatumumab Exposure During Pregnancy in Multiple Sclerosis

  2024cites this paper
• Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance

  2024cites this paper
• Impact of disease-modifying therapies on pregnancy outcomes in multiple sclerosis: a prospective cohort study from the German multiple sclerosis and pregnancy registry

  2024cites this paper
• Considerations for family planning in adolescent and young adults with multiple sclerosis

  2024cites this paper
• Pregnancy outcomes in adolescent and young adult patients with multiple sclerosis: A case series

  2024cites this paper
• Family planning and contraception in people with multiple sclerosis: perspectives for obstetricians, gynaecologists, and other health care professionals involved in reproductive planning

  2024influential citation
• Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Treated With Ocrelizumab

  2024cites this paper
• Optimizing Drug Selection in Children with Multiple Sclerosis: What Do We Know and What Remains Unanswered?

  2024cites this paper
• The challenge of pregnancy in women with multiple sclerosis.

  2023cites this paper
• "A qualitative study of multiple sclerosis specialists' experiences and perspectives in managing family planning in people with multiple sclerosis".

  2023cites this paper
• Optimizing the “Time to pregnancy” in women with multiple sclerosis: the OPTIMUS Delphi survey

  2023cites this paper
• Multiple Sklerose in Schwangerschaft und Stillzeit

  2023influential citation
• Intimate partner violence and multiple sclerosis

  2023cites this paper
• Frequency of diminished ovarian reserve in women with multiple sclerosis in Chile: An exploratory study.

  2023cites this paper
• Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis

  2023influential citation
• Exposure to medication for neurological disease in pregnancy – time to consider the long-term implications?

  2023cites this paper
• Disease modifying therapy and pregnancy outcomes in multiple sclerosis: A systematic review and meta-analysis.

  2023cites this paper
• Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception

  2023cites this paper
• Treatment of relapsing multiple sclerosis in Hungary – consensus recommendation from the Hungarian neuroimmunology society

  2023cites this paper
• Socioeconomic status of the elderly MS population compared to the general population: a nationwide Danish matched cross-sectional study

  2023cites this paper
• Planificación familiar en hombres y mujeres con esclerosis múltiple. Análisis del Registro Andaluz (2018-2022)

  2023cites this paper
• Monoclonal Antibodies in Pregnancy and Breastfeeding in Patients with Multiple Sclerosis: A Review and an Updated Clinical Guide

  2023cites this paper